ReviewFrontiers in medicine2021
Hepatitis B Virus Reactivation Associated With Therapeutic Interventions.
Review in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 39 citations in OpenAlex.
- Incidence of serious infections, herpes zoster and hepatitis B virus reactivation among patients with SLE: a cohort study using a health claims database in Japan.Lupus science & medicine · 2026Article
- Percutaneous Transhepatic Cholangiodrainage (PTCD)-Related Hepatitis B Virus Reactivation in Obstructive Jaundice.Journal of clinical medicine · 2026Article
- HBV reactivation during immunotherapy for hepatocellular carcinoma: risk factors and clinical management.Frontiers in immunology · 2026Review
- Article
- Development of an over-gap droplet digital PCR assay and evaluation of serum HBcrAg/qAnti-HBc as noninvasive markers for intrahepatic replication-competent HBV DNA in chronic hepatitis B patients with HBsAg loss.Emerging microbes & infections · 2025Article
- Antineoplastic agents-associated hepatitis B virus reactivation: Research progress and molecular mechanisms.Virus research · 2025Review
- The interplay between hepatitis B virus and antitumor drugs in the treatment of hepatocellular carcinoma.Clinical and experimental medicine · 2025Review
- Oncohepatology: Navigating liver injury in the era of modern cancer therapy.World journal of hepatology · 2025Review
- The role of bacterial outer membrane vesicles in inflammatory response of acute-on-chronic liver failure.Frontiers in microbiology · 2025Review
- Risk of HBV reactivation in HBV/HCV-co-infected HCV-treated patients: A single-center study.PloS one · 2025Article
- Viral etiologies of acute liver failure.World journal of virology · 2024Review
- Hepatitis B virus infection, infertility, and assisted reproduction.Journal of Zhejiang University. Science. B · 2024Review
- Real-world effectiveness, safety and immunogenicity of ocrelizumab in turkish multiple sclerosis patients: a single-center experience for 4-year follow-up.Acta neurologica Belgica · 2024Review
- Hepatitis B Reactivation and Liver Failure Because of COVID-19 Infection.ACG case reports journal · 2024Article
- Risk of hepatitis B virus reactivation in cancer patients undergoing treatment with tyrosine kinase-inhibitors.World journal of gastroenterology · 2024Article
- Overview of the immunological mechanisms in hepatitis B virus reactivation: Implications for disease progression and management strategies.World journal of gastroenterology · 2024Review
- The occurrence of immune-related adverse events is an independent risk factor both for serum HBsAg increase and HBV reactivation in HBsAg-positive cancer patients receiving PD-1 inhibitor combinational therapy.Frontiers in immunology · 2024Article
- HBV Vaccines: Advances and Development.Vaccines · 2023Review
- Risk of hepatitis B reactivation in patients with myeloproliferative neoplasms treated with ruxolitinib.World journal of hepatology · 2023Review
- Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies in the targeted therapy era.World journal of gastroenterology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis B virus (HBV) reactivation associated with various therapeutic interventions is an important cause of morbidity and mortality in patients with current or resolved HBV infection. Because no curative treatment for HBV infection is yet available, there are many individuals at risk for HBV reactivation in the general population. Populations at risk for HBV reactivation include patients who are currently infected with HBV or who have been exposed to HBV in the past. HBV reactivation and its potential consequences is a concern when these populations are exposed to anti-cancer chemotherapy, immunosuppressive or immunomodulatory therapies for the management of various malignancies, rheumatologic diseases, inflammatory bowel disease, or solid-organ or hematologic stem cell transplantation. Accordingly, it has become important to understand the basics of HBV reactivation and the mechanisms by which certain therapies are more susceptible to HBV reactivation. This review aims to raise the awareness of HBV reactivation and to understand the mechanisms and the risks of HBV reactivation in various clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.